Industry

Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trial Additional poster presentations show breadth of tislelizumab global clinical development program as single-agent treatment and in combination CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on … [Read more…]

  Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years Pivotal Phase 3 POETYK PSO clinical trials demonstrated superior efficacy of once-daily Sotyktu over placebo and twice-daily Otezla® (apremilast) … [Read more…]

TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the … [Read more…]

Next-generation assay combines 800+-gene panel with exome-wide methylation detection to provide novel genomic and epigenomic insights into tumor, tumor microenvironment and patient immune responses from a simple blood draw Researchers can access additional modular content to gain insight into and direct patient selection for IO, HRD and other targeted therapies with no need for additional … [Read more…]

First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years ROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and proven safety and efficacy profile Commercial team ready to launch with product available in the fourth quarter BOSTON–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology … [Read more…]

The reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the AeriSeal System REDWOOD CITY, Calif. & BARCELONA, Spain–(BUSINESS WIRE)–$LUNG #COPD–Please note the addition of citations at the end of the release dated Sept. 4, 2022. The updated … [Read more…]

Trek Health raised a Seed Round from leading investors including Lionheart Ventures, Founder Collective, Altman Capital, Ford Street Ventures, and others. SAN MATEO, Calif.–(BUSINESS WIRE)–Trek Health, the payment and insurance workflow automation platform for mental health provider groups, has closed an oversubscribed $2.7M Seed Round led by Lionheart Ventures. Trek Health eliminates the lengthy manual … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Healthcare Archiving Ediscovery Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering. The healthcare archiving eDiscovery market is poised to grow by $1.95 bn during 2022-2026, progressing at a CAGR of 10.19% during the forecast period. The report on the healthcare archiving eDiscovery market provides a holistic analysis, market size and forecast, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Laryngoscopes Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030” report has been added to ResearchAndMarkets.com’s offering. Laryngoscopes Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030 is built to visualize … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “US Friedreich’s Ataxia Market and Competitive Landscape – 2022” report has been added to ResearchAndMarkets.com’s offering. The report US Friedreich’s Ataxia Market and Competitive Landscape Highlights – 2022, provides comprehensive insights into Friedreich’s Ataxia pipeline products, Friedreich’s Ataxia epidemiology, Friedreich’s Ataxia market valuations and forecast, Friedreich’s Ataxia drugs sales and competitive landscape in … [Read more…]